Patient Blood Management Charité (PBM-Charité): Structured Detection, Differentiated Diagnostics and Therapy of Preoperative Anemia and Use of Machine Autotransfusion in Elective Interventions

Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · Dec 2, 2021

Keywords

ClinConnect Summary

The Patient Blood Management Charité (PBM-Charité) trial is studying ways to improve the care of patients with anemia who are scheduled for elective surgeries. Anemia is a condition where a person has low levels of red blood cells, which can make surgeries riskier due to potential complications from blood loss. The goal of this trial is to find better methods to manage anemia before surgery and to reduce the need for blood transfusions, which can have their own risks.

To be eligible for this trial, participants must be at least 18 years old, have anemia, and be scheduled for a surgery where there is a higher chance of needing a blood transfusion. Additionally, they must be insured by BARMER, unless they are part of a retrospective review of patients who meet similar criteria. Participants can expect to be closely monitored and receive specialized care aimed at managing their anemia. It's important to note that those with emergency surgeries, certain medical conditions, or who do not speak enough German may not qualify for the study. Overall, this trial aims to enhance patient safety and outcomes during surgical procedures.

Gender

ALL

Eligibility criteria

• Prospective:
• Inclusion Criteria:
• • age ≥ 18 years
• • male and female patients
• • patients eligible for inclusion: by the patient, preoperatively
• • patients who are insured with BARMER
• • patients with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion \> 10%
• additionally for the use of MAT:
• • indication of machine autotransfusion
• • high blood loss (\> 500ml / 10-20 % of estimated blood volume) beside of indication interventions (surgery under dual platelet inhibition, high individual bleeding risk, special antibodies / rare blood group, rejection of allogeneic blood)
• Exclusion Criteria:
• • patients with emergency interventions
• • rejection of study participation
• • pregnancy, elective caesarean section or breastfeeding
• • not enough German language skills
• • accommodation in an institution because of judicial or administrative order
• • employee of Charité
• • missing of declaration of consent
• Retrospective:
• Inclusion Criteria:
• • -Data since September 2021-February 2024 of patients who are not insured with BARMER with elective (N5) interventions with a transfusion probability \> 10% (indication list) with a preoperatively existing anemia
• additionally for the use of MAT:
• • indication of machine autotransfusion
• • high blood loss (\> 500ml / 10-20 % of estimated blood volume) beside of indication interventions (surgery under dual platelet inhibition, high individual bleeding risk, special antibodies / rare blood group, rejection of allogeneic blood)